MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 318564 | Name: Prednicarbate
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Prednicarbate is a Corticosteroid. The mechanism of action of prednicarbate is as a Corticosteroid Hormone Receptor Agonist. Prednicarbate is a synthetic non-halogenated double-ester derivative of the corticosteroid prednisolone with anti-inflammatory, antipruritic and vasoconstrictive properties. This agent also decreases the number of circulating lymphocytes by suppression of the production of vasodilators such as prostacyclin and nitric oxide.

Chemical Structure

Prednicarbate
CAS#73771-04-7

Theoretical Analysis

MedKoo Cat#: 318564

Name: Prednicarbate

CAS#: 73771-04-7

Chemical Formula: C27H36O8

Exact Mass: 488.2410

Molecular Weight: 488.58

Elemental Analysis: C, 66.38; H, 7.43; O, 26.20

Price and Availability

Size Price Availability Quantity
10mg USD 140.00
25mg USD 200.00
50mg USD 300.00
100mg USD 500.00
200mg USD 800.00
500mg USD 1,100.00
1g USD 1,700.00
2g USD 3,000.00
Show More
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
Prednicarbate; Hoe 777; Hoe-777; Dermatop E emollient; UNII-V901LV1K7D; prednisolone-17-ethylcarbonate-21-propionate; Batmen; Dermatop; HOE 777; HOE-777; Peitel;
IUPAC/Chemical Name
[2-[(8S,9S,10R,11S,13S,14S,17R)-17-ethoxycarbonyloxy-11-hydroxy-10,13-dimethyl-3-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-17-yl]-2-oxoethyl] propanoate
InChi Key
FNPXMHRZILFCKX-UHFFFAOYSA-N
InChi Code
InChI=1S/C27H36O8/c1-5-22(31)34-15-21(30)27(35-24(32)33-6-2)12-10-19-18-8-7-16-13-17(28)9-11-25(16,3)23(18)20(29)14-26(19,27)4/h9,11,13,18-20,23,29H,5-8,10,12,14-15H2,1-4H3
SMILES Code
CCC(=O)OCC(=O)C1(CCC2C1(CC(C3C2CCC4=CC(=O)C=CC34C)O)C)OC(=O)OCC
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Product Data
Instruction
View handling instruction
Biological target:
Prednicarbate is a topical corticosteroid agent.
In vitro activity:
TBD
In vivo activity:
The skin thinning effect of prednicarbate was compared with other corticosteroids (amcinonide, beta-methasone-17-valerate, clobetasol-17-propionate, diflorasone-17,21-diacetate, hydrocortisone-21-acetate). Prednicarbate produced a clear thinning of skin. Like other tested dermatocorticoids prednicarbate caused a significant atrophy of the mouse tail epidermis. By prednicarbate the 3H-thymidine triphosphate incorporation into epidermal DNA was inhibited. Reference: Skin Pharmacol. 1988;1(3):200-6. https://pubmed.ncbi.nlm.nih.gov/3272751/
Solvent mg/mL mM comments
Solubility
DMSO 98.0 200.58
Ethanol 49.0 100.29
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 488.58 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
Lubach D, Kietzmann M. Investigation of the skin thinning effect of prednicarbate and other corticoids in mouse skin. Skin Pharmacol. 1988;1(3):200-6. doi: 10.1159/000210774. PMID: 3272751.
In vitro protocol:
TBD
In vivo protocol:
Lubach D, Kietzmann M. Investigation of the skin thinning effect of prednicarbate and other corticoids in mouse skin. Skin Pharmacol. 1988;1(3):200-6. doi: 10.1159/000210774. PMID: 3272751.
1: Otero-Rivas MM, Ruiz-González I, Pérez-Bustillo A, Rodríguez-Prieto MÁ. Allergic contact dermatitis caused by prednicarbate presenting as chronic hand eczema. Contact Dermatitis. 2015 Jul;73(1):51-2. doi: 10.1111/cod.12374. Epub 2015 Apr 13. PubMed PMID: 25864447. 2: Bätz FM, Klipper W, Korting HC, Henkler F, Landsiedel R, Luch A, von Fritschen U, Weindl G, Schäfer-Korting M. Esterase activity in excised and reconstructed human skin--biotransformation of prednicarbate and the model dye fluorescein diacetate. Eur J Pharm Biopharm. 2013 Jun;84(2):374-85. doi: 10.1016/j.ejpb.2012.11.008. Epub 2012 Nov 29. PubMed PMID: 23201050. 3: Katzer K, Tietze J, Klein E, Heinemann V, Ruzicka T, Wollenberg A. Topical therapy with nadifloxacin cream and prednicarbate cream improves acneiform eruptions caused by the EGFR-inhibitor cetuximab - A report of 29 patients. Eur J Dermatol. 2010 Jan-Feb;20(1):82-4. doi: 10.1684/ejd.2010.0806. Epub 2009 Oct 2. PubMed PMID: 19797039. 4: Baspinar Y, Keck CM, Borchert HH. Development of a positively charged prednicarbate nanoemulsion. Int J Pharm. 2010 Jan 4;383(1-2):201-8. doi: 10.1016/j.ijpharm.2009.09.002. Epub 2009 Sep 10. PubMed PMID: 19747968. 5: Spencer CM, Wagstaff AJ. Prednicarbate: a review of its pharmacological properties and therapeutic use in the treatment of dermatological disorders. BioDrugs. 1998 Jan;9(1):61-86. PubMed PMID: 18020557. 6: Sánchez-Pérez J, Gala SP, Jiménez YD, Fraga J, Diez AG. Allergic contact dermatitis to prednicarbate presenting as lupus erythematosus. Contact Dermatitis. 2006 Oct;55(4):247-9. PubMed PMID: 16958925. 7: Gupta AK, Chow M. Prednicarbate (dermatop): a review. J Drugs Dermatol. 2004 Sep-Oct;3(5):553-6. Review. PubMed PMID: 15552608. 8: Bartosíková L, Frána L, Necas J, Frána P, Dzúrová J, Petrzelková J, Kollár P, Kotolová H. [Prednicarbate and cetirizin dihydrochloride in the treatment of atopic eczema in the acute phase in children]. Ceska Slov Farm. 2001 Jan;50(1):38-40. Czech. PubMed PMID: 11242833. 9: [Prednicarbate--the epidermis-corticoid among the topical corticoids]. Hautarzt. 1998 Apr;49(4 Suppl):1-16. German. PubMed PMID: 9595306. 10: Villas Martínez F, Navarro Echeverría JA, Joral Badás A, Garmendia Goitia FJ. Prednicarbate contact allergy. Contact Dermatitis. 1997 Dec;37(6):299-300. PubMed PMID: 9455638. 11: Lange K, Gysler A, Bader M, Kleuser B, Korting HC, Schäfer-Korting M. Prednicarbate versus conventional topical glucocorticoids: pharmacodynamic characterization in vitro. Pharm Res. 1997 Dec;14(12):1744-9. PubMed PMID: 9453063. 12: Gysler A, Lange K, Korting HC, Schäfer-Korting M. Prednicarbate biotransformation in human foreskin keratinocytes and fibroblasts. Pharm Res. 1997 Jun;14(6):793-7. PubMed PMID: 9210199. 13: Aliaga A, Rodríguez M, Armijo M, Bravo J, Avila AL, Mascaro JM, Ferrando J, Del Rio R, Lozano R, Balaguer A. Double-blind study of prednicarbate versus fluocortin butyl ester in atopic dermatitis. Int J Dermatol. 1996 Feb;35(2):131-2. PubMed PMID: 8850046. 14: Korting HC, Zienicke H, Braun-Falco O, Bork K, Milbradt R, Nolting S, Schöpf E, Tronnier H. Modern topical glucocorticoids and anti-infectives for superinfected atopic eczema: do prednicarbate and didecyldimethylammoniumchloride form a rational combination? Infection. 1994 Nov-Dec;22(6):390-4. Review. Erratum in: Infection 1995 Jan-Feb;23(1):67. PubMed PMID: 7698835. 15: Barth J, Hochhaus G, Derendorf H, Lehr KH, Höhler T, Moellmann H. Prednicarbate after different forms of administration. Plasma levels of drug and metabolites and effects on endogenous cortisol levels in humans. Curr Probl Dermatol. 1993;21:147-56. PubMed PMID: 8299368. 16: Ulrich R, Andresen I. [Treatment of acute episodes of atopic dermatitis. Double-blind comparative study with 0.05% halometasone cream versus 0.25% prednicarbate cream]. Fortschr Med. 1991 Dec 20;109(36):741-4. German. PubMed PMID: 1778534. 17: Dunkel FG, Elsner P, Burg G. Allergic contact dermatitis from prednicarbate. Contact Dermatitis. 1991 Jan;24(1):59-60. PubMed PMID: 2044373. 18: Lubach D, Platschek H. [Steroid-induced damage of the facial skin following use of prednicarbate]. Hautarzt. 1990 Jan;41(1):43-5. German. PubMed PMID: 2138141. 19: Lubach D, Kietzmann M. Investigation of the skin thinning effect of prednicarbate and other corticoids in mouse skin. Skin Pharmacol. 1988;1(3):200-6. PubMed PMID: 3272751. 20: Schulz H. [Photographic follow-up of the topical use of prednicarbate preparations in inflammatory dermatoses]. Z Hautkr. 1986;61 Suppl 1:51-61. German. PubMed PMID: 3705673.